Overview
- Eli Lilly said on April 30th that first‑quarter revenue rose 56% to $19.8 billion and it raised 2026 guidance to $82–$85 billion in sales and $35.50–$37.00 in adjusted EPS.
- Mounjaro and Zepbound, injectable GLP‑1 drugs for diabetes and weight loss, drove the surge with about $12.8 billion in combined quarterly sales.
- Foundayo, Lilly’s new oral GLP‑1 pill, launched after FDA approval with company‑reported early use topping 20,000 patients and 8,000 prescribers.
- Prescription trackers cited by Reuters showed 1,390, 3,707, and 5,612 U.S. Foundayo prescriptions in weeks one through three, which some analysts called a data‑capture gap rather than weak demand.
- A single FDA adverse‑event report of serious liver injury in a Foundayo patient prompted brief selling, but Wolfe Research and RBC said Lilly judged the case not drug‑related and kept Outperform views, as Barclays ($1,400), Morgan Stanley ($1,344), and Cantor ($1,230) raised or reaffirmed targets.